aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Rating of “Hold” from Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $17.00.

ATYR has been the topic of several recent research reports. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Freedom Capital raised shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. Finally, Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th.

aTyr Pharma Trading Up 1.3%

NASDAQ:ATYR opened at $0.49 on Tuesday. The stock’s 50-day moving average is $0.51 and its 200-day moving average is $0.71. The stock has a market cap of $48.24 million, a P/E ratio of -0.67 and a beta of 0.54. aTyr Pharma has a 1-year low of $0.40 and a 1-year high of $6.50.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. As a group, equities analysts forecast that aTyr Pharma will post -0.66 EPS for the current year.

Insider Buying and Selling at aTyr Pharma

In other aTyr Pharma news, Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction dated Wednesday, May 27th. The stock was purchased at an average price of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director directly owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 5.75% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System bought a new position in aTyr Pharma during the 2nd quarter worth approximately $28,000. Legal & General Group Plc bought a new position in shares of aTyr Pharma during the second quarter valued at about $49,000. Prudential Financial Inc. bought a new stake in shares of aTyr Pharma in the second quarter worth about $63,000. Oxford Asset Management LLP purchased a new position in aTyr Pharma during the 2nd quarter valued at about $70,000. Finally, Creative Planning purchased a new position in aTyr Pharma during the 2nd quarter valued at about $74,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.